CJC-1295 DAC

Growth Hormone Secretagogues

aka CJC1295 DAC · CJC-1295 with DAC · DAC-GRF

Compare

Formula

MW (Da)

Half-life

~6–8 days (DAC-mediated albumin binding)

Saves

Overview

CJC-1295 DAC is a modified GHRH(1-29) analog engineered with a Drug Affinity Complex that covalently binds serum albumin after injection, extending its half-life to roughly 6–8 days. The retrieved literature includes randomized placebo-controlled ascending-dose trials in healthy humans showing sustained GH and IGF-1 elevation with preserved pulsatility.

Mechanism

CJC-1295 activates the GHRH receptor on pituitary somatotrophs through standard cAMP/PKA signaling, but unlike native short-lived GHRH fragments, it persists because the DAC moiety enables covalent association with serum albumin after injection. The result is sustained GH and IGF-1 elevation while pulsatility is preserved rather than flattened into a continuous infusion-like pattern. In healthy men, a single injection increased trough and mean GH secretion while preserving GH pulsatility. Estimated terminal half-life is 5.8–8.1 days. Antidoping literature treats it as a prohibited GH-releasing factor analog.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Sustained GH and IGF-1 elevation in human PK/PD trials

In randomized placebo-controlled ascending-dose human trials, single SC CJC-1295 injections increased plasma GH 2- to 10-fold for at least 6 days and IGF-1 1.5- to 3-fold for 9 to 11 days. Estimated half-life 5.8–8.1 days.

[teichman-cjc1295-jcem-2006]

clinical

IGF-1 elevation maintained with repeated weekly or biweekly dosing

Repeated weekly or biweekly SC dosing kept IGF-1 above baseline for up to 28 days in healthy volunteers.

[teichman-cjc1295-jcem-2006]

clinical

Preserved GH pulsatility (vs. flat exposure)

In healthy men, a single injection increased trough and mean GH secretion while preserving GH pulsatility, rather than producing a continuous-infusion-like pattern.

[cjc1295-pulsatility-pubmed]

clinical

Reported side effects

No serious adverse reactions reported in the ascending-dose trial
clinical
In the accessible human trial abstract, no serious adverse reactions were reported, and the compound was described as safe and relatively well tolerated, particularly at 30 and 60 μg/kg.
Long-term and minor-event incidence not characterized
anecdotal
Detailed adverse-event tables were not accessible in the retrieved text, and longer-term safety with sustained weekly or biweekly dosing has not been characterized in published primary trials.

Dosing notes

Human studies used subcutaneous administration in single ascending doses (30–60 μg/kg best supported) and in weekly or biweekly repeated dosing schedules. More granular cohort doses were not visible in the retrieved abstract; treat any single specific microgram-per-kilogram value as study-protocol level, not consensus clinical dosing.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Research supplier data are consistent with frozen storage. One Sigma-linked listing reports -80/-20 °C storage with shipping at 4 °C; other CJC-1295 DAC product pages list lyophilized storage at -20 °C and 4 °C after reconstitution, advising against repeated freeze-thaw cycles. These are vendor-level handling instructions, not peer-reviewed pharmaceutical stability.

Vendors carrying CJC-1295 DAC

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about CJC-1295 DAC.

No questions yet. Be the first to ask.

References

[teichman-cjc1295-jcem-2006]
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor-I secretion by CJC-1295
Teichman SL et al. · 2006 · Journal of Clinical Endocrinology & Metabolism
Source
[cjc1295-pulsatility-pubmed]
CJC-1295: preserved GH pulsatility in healthy men
Ionescu M, Frohman LA · PubMed
Source
[cjc1295-sigma]
CJC-1295 DAC product listing (Targetmol via Sigma-Aldrich)
Targetmol / Sigma-Aldrich · Sigma-Aldrich product listing
Source

Reported benefits

Sustained GH and IGF-1 elevation in human PK/PD trials

IGF-1 elevation maintained with repeated weekly or biweekly dosing

Preserved GH pulsatility (vs. flat exposure)

No serious adverse reactions reported in the ascending-dose trial

Long-term and minor-event incidence not characterized

Discussion